Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- April 1, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- March 11, 2024 Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
- March 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- February 27, 2024 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- February 26, 2024 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- February 20, 2024 Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
- February 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- January 26, 2024 Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
- January 8, 2024 Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
- January 5, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 31 - 40 of 305